BR9106303A - Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla - Google Patents
Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multiplaInfo
- Publication number
- BR9106303A BR9106303A BR919106303A BR9106303A BR9106303A BR 9106303 A BR9106303 A BR 9106303A BR 919106303 A BR919106303 A BR 919106303A BR 9106303 A BR9106303 A BR 9106303A BR 9106303 A BR9106303 A BR 9106303A
- Authority
- BR
- Brazil
- Prior art keywords
- multiple sclerosis
- symptoms
- human
- imonogenous
- diagnosising
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50255990A | 1990-03-30 | 1990-03-30 | |
| PCT/US1991/002218 WO1991015225A1 (en) | 1990-03-30 | 1991-03-29 | Multiple sclerosis t-cell receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9106303A true BR9106303A (pt) | 1993-04-13 |
Family
ID=23998362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR919106303A BR9106303A (pt) | 1990-03-30 | 1991-03-29 | Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0522091B9 (pt) |
| JP (1) | JPH05507911A (pt) |
| AT (1) | ATE210721T1 (pt) |
| AU (1) | AU651350B2 (pt) |
| BR (1) | BR9106303A (pt) |
| CA (1) | CA2078549C (pt) |
| DE (1) | DE69132863T2 (pt) |
| DK (1) | DK0522091T5 (pt) |
| ES (1) | ES2169021T3 (pt) |
| HU (1) | HU217847B (pt) |
| IL (3) | IL97709A (pt) |
| NO (1) | NO308611B1 (pt) |
| WO (1) | WO1991015225A1 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207645B1 (en) | 1989-03-21 | 2001-03-27 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
| US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| DK0527199T4 (da) * | 1990-05-01 | 2000-12-04 | Univ Leland Stanford Junior | Præparater til anvendelse ved en fremgangsmåde tilbehandling af et menneske, der lider afdissemineret sclerose |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| CA2101065A1 (en) * | 1991-01-22 | 1992-07-23 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| WO1993012814A2 (en) * | 1991-12-24 | 1993-07-08 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
| US5891435A (en) * | 1993-04-16 | 1999-04-06 | Research Corporation Technologies, Inc. | Methods and compositions for delaying or preventing the onset of autoimmune disease |
| WO1996001329A1 (en) * | 1994-07-01 | 1996-01-18 | Connective Therapeutics Inc. | Methods for diagnosing an immune-related disease and choosing an immune-related therapy |
| AU4278296A (en) * | 1994-10-25 | 1996-05-15 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
| IL114458A0 (en) * | 1995-07-05 | 1995-11-27 | Yeda Res & Dev | Therapeutic preparations for treatment of T cell mediated diseases |
| US20020009448A1 (en) * | 1997-09-19 | 2002-01-24 | Leslie P. Weiner | T-cell vaccination for the treatment of multiple sclerosis |
| ATE367823T1 (de) | 2000-05-24 | 2007-08-15 | Us Health | E-selectin zur behandlung oder vorbeugung von schlaganfall |
| HU229377B1 (hu) * | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
| US7658926B2 (en) | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| US7744893B2 (en) | 2002-06-05 | 2010-06-29 | Baylor College Of Medicine | T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same |
| NZ537403A (en) * | 2002-06-05 | 2009-10-30 | Baylor College Medicine | T cell receptor CDR3 sequences and methods for detection |
| PL214283B1 (pl) | 2002-08-08 | 2013-07-31 | Baylor College Medicine | Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2072356A1 (en) * | 1989-12-29 | 1991-06-30 | James L. Urban | Diagnosis and treatment of diseases |
-
1991
- 1991-03-28 IL IL9770991A patent/IL97709A/xx not_active IP Right Cessation
- 1991-03-28 IL IL165071A patent/IL165071A/en not_active IP Right Cessation
- 1991-03-29 AT AT91910085T patent/ATE210721T1/de not_active IP Right Cessation
- 1991-03-29 DE DE69132863T patent/DE69132863T2/de not_active Expired - Lifetime
- 1991-03-29 BR BR919106303A patent/BR9106303A/pt not_active Application Discontinuation
- 1991-03-29 EP EP91910085A patent/EP0522091B9/en not_active Expired - Lifetime
- 1991-03-29 AU AU78989/91A patent/AU651350B2/en not_active Expired
- 1991-03-29 JP JP91509347A patent/JPH05507911A/ja active Pending
- 1991-03-29 ES ES91910085T patent/ES2169021T3/es not_active Expired - Lifetime
- 1991-03-29 HU HU9203100A patent/HU217847B/hu unknown
- 1991-03-29 CA CA002078549A patent/CA2078549C/en not_active Expired - Lifetime
- 1991-03-29 WO PCT/US1991/002218 patent/WO1991015225A1/en active IP Right Grant
- 1991-03-29 DK DK91910085T patent/DK0522091T5/da active
-
1992
- 1992-09-29 NO NO923778A patent/NO308611B1/no not_active IP Right Cessation
-
2004
- 2004-11-07 IL IL16507104A patent/IL165071A0/xx active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05507911A (ja) | 1993-11-11 |
| WO1991015225A1 (en) | 1991-10-17 |
| EP0522091A1 (en) | 1993-01-13 |
| DK0522091T5 (da) | 2008-06-23 |
| HU217847B (hu) | 2000-04-28 |
| DK0522091T3 (da) | 2002-04-08 |
| NO308611B1 (no) | 2000-10-02 |
| HU9203100D0 (en) | 1992-12-28 |
| AU7898991A (en) | 1991-10-30 |
| ATE210721T1 (de) | 2001-12-15 |
| CA2078549A1 (en) | 1991-10-01 |
| IL165071A (en) | 2008-06-05 |
| AU651350B2 (en) | 1994-07-21 |
| DE69132863T2 (de) | 2002-06-20 |
| ES2169021T3 (es) | 2002-07-01 |
| HUT63334A (en) | 1993-08-30 |
| NO923778L (no) | 1992-11-16 |
| EP0522091B9 (en) | 2007-11-21 |
| EP0522091B1 (en) | 2001-12-12 |
| IL165071A0 (en) | 2005-12-18 |
| EP0522091A4 (en) | 1993-05-26 |
| CA2078549C (en) | 2006-07-11 |
| IL97709A (en) | 2005-05-17 |
| IL97709A0 (en) | 1992-06-21 |
| NO923778D0 (no) | 1992-09-29 |
| DE69132863D1 (de) | 2002-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9106303A (pt) | Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla | |
| Kakimoto et al. | Isolation of T cell line capable of protecting mice against collagen-induced arthritis. | |
| Scott et al. | Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. | |
| KR920700674A (ko) | 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법 | |
| BR9913323A (pt) | Processo para vacinar um mamìfero contra umestado doentio, composição de vacina, uso de umcomposto, e, combinação de componentes paraadministração separada, sequencial ouconcomitante no processo | |
| PT912898E (pt) | Metodo imunologico de deteccao de anticorpos dirigidos contra a transglutaminase (ttg) utilizacao de ttg para o diagnostico e controlo de terapia assim como agente farmaceutico oral contendo ttg | |
| Britton et al. | Immunoreactivity of a 70 kD protein purified from Mycobacterium bovis Bacillus Calmette-Guerin by monoclonal antibody affinity chromatography. | |
| TR199801722T2 (xx) | Peptit imm�nojenler. | |
| BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
| GB2255093A (en) | Hiv-1 core protein fragments | |
| JP3554319B2 (ja) | ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物 | |
| DE69638024D1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
| GR3029774T3 (en) | Method of preparing a radioactive rhenium complex solution. | |
| AR033832A1 (es) | Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo | |
| NO941370D0 (no) | Rekombitope peptider | |
| EP0674661A4 (en) | TITRATION AND TREATMENT FOR DEMYELINIZING DISEASES SUCH AS MULTIPLE SCLEROSIS. | |
| EP0482089A4 (en) | Methods of treating or preventing autoimmune uveoretinitis in mammals | |
| PT1025849E (pt) | Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase | |
| Takaoka et al. | Second case of zoonotic Onchocerca infection in a resident of Oita in Japan | |
| SE9001105D0 (sv) | New methods foer diagnosis of tuberculosis | |
| Fagiolo et al. | Quantitative and qualitative analysis of anti-tetanus toxoid antibody response in the elderly. Humoral immune response enhancement by thymostimulin | |
| Brown et al. | Partial purification of antigens from eggs of Schistosoma mansoni that elicit delayed hypersensitivity | |
| NZ328940A (en) | Methods and use t cell epitopes of lol p v ryegrass pollen antigens | |
| NZ515332A (en) | Lawsonia derived gene and related SodC polypeptides, peptides and proteins and their uses | |
| US20060039920A1 (en) | Orientia tsutsugamushi truncated recombinant outer membrane protein (r47) and (r56) vaccines diagnostics and therapeutics for scrub typhus and HIV infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| FC | Decision: refusal | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C12Q 1/6883 (2018.01), A61K 39/00 (2006.0 |